Fasting is deeply entrenched in evolution, yet its potential applications to today's most common, disabling neurological diseases remain relatively unexplored. Fasting induces an altered metabolic state that optimizes neuron bioenergetics, plasticity, and resilience in a way that may counteract a broad array of neurological disorders. In both animals and humans, fasting prevents and treats the metabolic syndrome, a major risk factor for many neurological diseases. In animals, fasting probably prevents the formation of tumors, possibly treats established tumors, and improves tumor responses to chemotherapy. In human cancers, including cancers that involve the brain, fasting ameliorates chemotherapy-related adverse effects and may protect normal cells from chemotherapy. Fasting improves cognition, stalls age-related cognitive decline, usually slows neurodegeneration, reduces brain damage and enhances functional recovery after stroke, and mitigates the pathological and clinical features of epilepsy and multiple sclerosis in animal models. Primarily due to a lack of research, the evidence supporting fasting as a treatment in human neurological disorders, including neurodegeneration, stroke, epilepsy, and multiple sclerosis, is indirect or non-existent. Given the strength of the animal evidence, many exciting discoveries may lie ahead, awaiting future investigations into the viability of fasting as a therapy in neurological disease.
Keywords: cancer; epilepsy; fasting; metabolic syndrome; multiple sclerosis; neurodegeneration; neurological disease; stroke; therapy.
Conflict of interest statement
The author declares no conflict of interest.
Glutamate Receptor Antibodies in Neurological Diseases: Anti-AMPA-GluR3 Antibodies, anti-NMDA-NR1 Antibodies, anti-NMDA-NR2A/B Antibodies, anti-mGluR1 Antibodies or anti-mGluR5 Antibodies Are Present in Subpopulations of Patients With Either: Epilepsy, Encephalitis, Cerebellar Ataxia, Systemic Lupus Erythematosus (SLE) and Neuropsychiatric SLE, Sjogren's Syndrome, Schizophrenia, Mania or Stroke. These Autoimmune Anti-Glutamate Receptor Antibodies Can Bind Neurons in Few Brain Regions, Activate Glutamate Receptors, Decrease Glutamate Receptor's Expression, Impair Glutamate-Induced Signaling and Function, Activate Blood Brain Barrier Endothelial Cells, Kill Neurons, Damage the Brain, Induce Behavioral/Psychiatric/Cognitive Abnormalities and Ataxia in Animal Models, and Can Be Removed or Silenced in Some Patients by ImmunotherapyM Levite. J Neural Transm (Vienna) 121 (8), 1029-75. PMID 25081016. - ReviewGlutamate is the major excitatory neurotransmitter of the Central Nervous System (CNS), and it is crucially needed for numerous key neuronal functions. Yet, excess glutam …
Impact of Intermittent Fasting on Health and Disease ProcessesMP Mattson et al. Ageing Res Rev 39, 46-58. PMID 27810402. - ReviewHumans in modern societies typically consume food at least three times daily, while laboratory animals are fed ad libitum. Overconsumption of food with such eating patter …
Idiopathic Focal Epilepsies: The "Lost Tribe"DK Pal et al. Epileptic Disord 18 (3), 252-88. PMID 27435520. - ReviewThe term idiopathic focal epilepsies of childhood (IFE) is not formally recognised by the ILAE in its 2010 revision (Berg et al., 2010), nor are its members and boundarie …
Adenosine Receptors and Neurological Disease: Neuroprotection and NeurodegenerationTW Stone et al. Handb Exp Pharmacol (193), 535-87. PMID 19639293. - ReviewAdenosine receptors modulate neuronal and synaptic function in a range of ways that may make them relevant to the occurrence, development and treatment of brain ischemic …
The Pharmacology of Neurotrophic Treatment With Cerebrolysin: Brain Protection and Repair to Counteract Pathologies of Acute and Chronic Neurological DisordersE Masliah et al. Drugs Today (Barc) 48 Suppl A, 3-24. PMID 22514792. - ReviewNeurotrophic factors are considered as part of the therapeutic strategy for neurological disorders like dementia, stroke and traumatic brain injury. Cerebrolysin is a neu …